Pancreatic Cancer Trial, Recruiting NCT06271291 Sponsor: Mayo Clinic Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06271291
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Based on family history or genetics:

  • People aged 50 or older who have two or more relatives on the same side of the family diagnosed with pancreatic cancer, where at least two of those relatives are closely related to each other and at least one is a close blood relative (parent, sibling, or child) of the person joining
  • People aged 50 or older who have two or more close blood relatives (parents, siblings, or children) diagnosed with pancreatic cancer
  • People aged 50 or older who carry a known high-risk gene change in one of these genes: CDKN2A/p16, STK11 (linked to Peutz-Jeghers syndrome), or PRSS1 (linked to hereditary pancreatitis)
  • People aged 50 or older who have one or more relatives with pancreatic cancer and also carry a known high-risk gene change in one of these genes: ATM, BRCA1, BRCA2, PALB2, TP53, or genes linked to Lynch syndrome (MLH1, MSH2, MSH6, PMS2, or EPCAM)

Based on pancreatic cysts:

  • People aged 18 or older who have pancreatic cysts that meet specific concerning or high-risk features, such as: a blocked bile duct caused by a cyst in the head of the pancreas; a growth inside the cyst measuring 5mm or more; a main pancreatic duct measuring 10mm or more; a narrowed pancreatic duct with upstream widening of 6mm or more; a cyst 3cm or larger; a smaller growth inside the cyst; thickened or inflamed cyst walls; a main duct between 5–9mm; a history of pancreatitis; swollen lymph nodes; a raised CA 19-9 blood marker; or a cyst that has grown 5mm or more over two years

Who may not be able to join:

  • People who are not able to give informed consent to participate
  • People who have received a bone marrow transplant from another person, or who currently have an active blood cancer such as leukaemia or lymphoma
  • People who have a current or past diagnosis of pancreatic cancer, or who have had their entire pancreas removed
  • People who are currently incarcerated in prison
  • People who are not able to speak or read English

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ann L. Oberg, PhD, Mayo Clinic in Rochester

Phone: 855-776-0015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
12 December 2024
Est. completion
1 November 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Develop a biobank of biospecimens and data of subjects without pancreatic cancer who are at high risk for pancreatic cancer; Follow subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov